BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koola MM. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. Psychiatry Res 2020;293:113409. [PMID: 32829072 DOI: 10.1016/j.psychres.2020.113409] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Neha, Parvez S. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease. Ageing Res Rev 2022;85:101815. [PMID: 36529440 DOI: 10.1016/j.arr.2022.101815] [Reference Citation Analysis]
2 Castillo C, Bravo-arrepol G, Wendt A, Saez-orellana F, Millar C, Burgos CF, Gavilán J, Pacheco C, Ahumada-rudolph R, Napiórkowska M, Pérez C, Becerra J, Fuentealba J, Cabrera-pardo JR. Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity. JAD 2022. [DOI: 10.3233/jad-220935] [Reference Citation Analysis]
3 Nanaki SG, Spyrou K, Veneti P, Karouta N, Gournis D, Baroud TN, Barmpalexis P, Bikiaris DN. L-Cysteine Modified Chitosan Nanoparticles and Carbon-Based Nanostructures for the Intranasal Delivery of Galantamine. Polymers 2022;14:4004. [DOI: 10.3390/polym14194004] [Reference Citation Analysis]
4 Morató X, Pytel V, Jofresa S, Ruiz A, Boada M. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. IJMS 2022;23:9305. [DOI: 10.3390/ijms23169305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Majidazar R, Rezazadeh-Gavgani E, Sadigh-Eteghad S, Naseri A. Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews. Eur J Clin Pharmacol 2022. [PMID: 35881170 DOI: 10.1007/s00228-022-03363-6] [Reference Citation Analysis]
6 Knehtl M, Petreski T, Piko N, Ekart R, Bevc S. Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient. Front Psychiatry 2022;13:882860. [DOI: 10.3389/fpsyt.2022.882860] [Reference Citation Analysis]
7 Ghafoori S, Shalbaf A. Predicting conversion from MCI to AD by integration of rs-fMRI and clinical information using 3D-convolutional neural network. Int J Comput Assist Radiol Surg 2022. [PMID: 35419720 DOI: 10.1007/s11548-022-02620-4] [Reference Citation Analysis]
8 Elmaidomy AH, Abdelmohsen UR, Alsenani F, Aly HF, Eldin Shams SG, Younis EA, Ahmed KA, Sayed AM, Owis AI, Afifi N, El Amir D. The anti-Alzheimer potential of Tamarindus indica: an in vivo investigation supported by in vitro and in silico approaches. RSC Adv 2022;12:11769-85. [PMID: 35481086 DOI: 10.1039/d2ra01340a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kinney J, Osse AML, Lamb B, Oblack A, Palkowitz AD, Belas FJ. Role of Animal Models in Alzheimer’s Disease Drug Development. Alzheimer's Disease Drug Development 2022. [DOI: 10.1017/9781108975759.008] [Reference Citation Analysis]
10 Bai MY, Lovejoy DB, Guillemin GJ, Kozak R, Stone TW, Koola MM. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders. Complex Psychiatry 2021;7:19-33. [PMID: 35141700 DOI: 10.1159/000515066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Vishwas S, Singh SK, Gulati M, Awasthi A, Khursheed R, Corrie L, Kumar R, Collet T, Loebenberg R, Porwal O, Gupta S, Jha NK, Gupta PK, Devkota HP, Chellappan DK, Gupta G, Adams J, Dua K. Harnessing the therapeutic potential of fisetin and its nanoparticles: Journey so far and road ahead. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Tanaka M, Török N, Vécsei L. Novel Pharmaceutical Approaches in Dementia. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-030-62059-2_444] [Reference Citation Analysis]
13 Wang Z, Yang B. Polypharmacology in Clinical Applications: Neurological Polypharmacology. Polypharmacology 2022. [DOI: 10.1007/978-3-031-04998-9_6] [Reference Citation Analysis]
14 Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study. Cogn Behav Neurol 2021;34:288-94. [PMID: 34851866 DOI: 10.1097/WNN.0000000000000285] [Reference Citation Analysis]
15 Hoque MM, Bari MA, Khan MW. Rh(II)‐mediated one‐pot synthesis of dihydrobenzofuran and spiro[2.5]oct‐1‐ene: Experimental and DFT studies. J Phys Org Chem. [DOI: 10.1002/poc.4300] [Reference Citation Analysis]
16 Tanaka M, Török N, Tóth F, Szabó Á, Vécsei L. Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines 2021;9. [PMID: 34440101 DOI: 10.3390/biomedicines9080897] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
17 Müller T, Mueller BK, Riederer P. Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 2021;10:873. [PMID: 33921342 DOI: 10.3390/cells10040873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Tanaka M, Török N, Vécsei L. Novel Pharmaceutical Approaches in Dementia. NeuroPsychopharmacotherapy 2021. [DOI: 10.1007/978-3-319-56015-1_444-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Nazam N, Farhana A, Shaikh S. Recent Advances in Alzheimer’s Disease in Relation to Cholinesterase Inhibitors and NMDA Receptor Antagonists. Autism Spectrum Disorder and Alzheimer's Disease 2021. [DOI: 10.1007/978-981-16-4558-7_8] [Reference Citation Analysis]
20 Gan J, Wang M, Liu S, Chen Z, Wang XD, Ji Y. Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking. Am J Alzheimers Dis Other Demen 2021;36:15333175211053134. [PMID: 34841902 DOI: 10.1177/15333175211053134] [Reference Citation Analysis]
21 Török N, Tanaka M, Vécsei L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. Int J Mol Sci 2020;21:E9338. [PMID: 33302404 DOI: 10.3390/ijms21249338] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
22 Tanaka M, Vécsei L. Monitoring the Redox Status in Multiple Sclerosis. Biomedicines 2020;8:E406. [PMID: 33053739 DOI: 10.3390/biomedicines8100406] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
23 Koola MM. Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond. Hum Psychopharmacol 2021;36:1-16. [PMID: 32965756 DOI: 10.1002/hup.2758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]